ALX ONCOLOGY HOLDINGS INC (ALXO) AI Dilution Summary

ALX Oncology reported cash of $138,229,000 at 2026-06-30 against estimated monthly burn of $5,352,333. Its active funding channel is the ATM program with Cantor Fitzgerald & Co. and UBS Securities LLC, authorised to $150,000,000. Through that program, 3,183,109 shares were sold since the program began through 2026-06-30, and sales after 2026-06-30 are not yet reported.